Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Immune dysregulation from a novel CTLA-4 haploinsufficiency variant.

Journal of human immunity·2026
Same author

CD28 and TCR differentially impact naïve and memory T cell responses.

Discovery immunology·2025
Same author

Reply: Hepatopulmonary syndrome associated with common variable immunodeficiency: Is it reasonable to investigate?

Hepatology communications·2024
Same author

Re: Association of Cytomegalovirus (CMV) DNAemia With Long-term Mortality in a Randomized Trial of Preemptive Therapy and Antiviral Prophylaxis for Prevention of CMV Disease in High-Risk Donor Seropositive, Recipient Seronegative Liver Transplant Recipients.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same author

Common variable immunodeficiency disorder-related liver disease is common and results in portal hypertension and an increased risk of death.

Hepatology communications·2023
Same author

Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.

Proceedings of the National Academy of Sciences of the United States of America·2023

Related Experiment Video

Updated: Feb 19, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K

CTLA-4: a moving target in immunotherapy.

Behzad Rowshanravan1, Neil Halliday1, David M Sansom1

  • 1Institute of Immunity and Transplantation, Division of Infection & Immunity, University College London, Royal Free Hospital, London, United Kingdom.

Blood
|November 10, 2017
PubMed
Summary

CD28 and CTLA-4 are key regulators of T-cell function. Understanding their biology is crucial for developing immune therapies for cancer and autoimmune diseases.

More Related Videos

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.9K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.4K

Related Experiment Videos

Last Updated: Feb 19, 2026

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.1K
Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
09:53

Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens

Published on: February 6, 2017

11.9K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

1.4K

Area of Science:

  • Immunology
  • Molecular Biology
  • Cancer Research

Background:

  • CD28 and CTLA-4 are immunoglobulin-related receptors involved in T-cell immune regulation.
  • This family includes stimulatory (CD28, ICOS) and inhibitory (CTLA-4, PD-1, BTLA, TIGIT) receptors.
  • These pathways are increasingly targeted for cancer immunotherapy and treatment of autoimmune conditions.

Purpose of the Study:

  • To provide a comprehensive overview of the CD28/CTLA-4 pathway.
  • To highlight the biological mechanisms underlying T-cell regulation by these receptors.
  • To establish a framework for understanding therapeutic interventions targeting this pathway.

Main Methods:

  • Review of existing scientific literature on CD28, CTLA-4, and related immune checkpoints.
  • Analysis of the roles of stimulatory and inhibitory receptors in T-cell function.
  • Discussion of therapeutic strategies involving immune checkpoint blockade.

Main Results:

  • CD28 and CTLA-4 play critical, often opposing, roles in T-cell activation and inhibition.
  • Dysregulation of the CD28/CTLA-4 pathway contributes to various diseases, including cancer and autoimmunity.
  • Targeting these pathways offers significant therapeutic potential.

Conclusions:

  • The CD28/CTLA-4 pathway is a central hub for T-cell immune responses.
  • A deep understanding of this pathway is essential for advancing immunomodulatory therapies.
  • Future research should continue to explore the therapeutic manipulation of these immune checkpoints.